Verona Pharma Announces November 2021 Investor Conference Participation
Verona Pharma plc (Nasdaq: VRNA) announced its participation in three investor conferences this November 2021. David Zaccardelli, CEO, will present at the Stifel Virtual Healthcare Conference on November 15, the Jefferies London Healthcare Conference on November 18, and the Piper Sandler Annual Virtual Healthcare Conference on November 29. The presentations will cover Verona's innovative respiratory therapies, including ensifentrine, which targets COPD and other respiratory diseases. Webcasts of the presentations will be available on the company's investor relations page.
- Verona Pharma is actively engaging with investors through multiple conferences, which can enhance visibility and investor interest.
- The focus on innovative therapies like ensifentrine positions Verona Pharma strongly in the respiratory disease market.
- None.
LONDON and RALEIGH, N.C., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., President and Chief Executive Officer, will present at the following investor conferences in November 2021:
Stifel 2021 Virtual Healthcare Conference
Date: Monday, November 15
Time: 9:20 AM EST / 2:20 PM GMT
Jefferies London Healthcare Conference
Date: Thursday, November 18
Time: 3:00 AM EST / 8:00 AM GMT
Piper Sandler 33rd Annual Virtual Healthcare Conference
Date: Monday, November 29
Presentation available on-demand starting at 10:00 AM EST / 3:00 PM GMT on Monday, November 22
A webcast of each conference presentation will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com.
For further information please contact:
| Verona Pharma plc | US Tel: +1-833-417-0262 UK Tel: +44 (0)203 283 4200 |
| Victoria Stewart, Director of Investor Relations and Communications | info@veronapharma.com |
| Argot Partners (US Investor Enquiries) | Tel: +1-212-600-1902 verona@argotpartners.com |
| Kimberly Minarovich / Michael Barron | |
| Optimum Strategic Communications (International Media and European Investor Enquiries) | Tel: +44 (0)203 950 9144 verona@optimumcomms.com |
| Mary Clark / Stella Lempidaki / Zoe Bolt |
About Verona Pharma
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma’s product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment. Two additional formulations of ensifentrine are in Phase 2 development for the treatment of COPD: dry powder inhaler (“DPI”) and pressurized metered-dose inhaler (“pMDI”). Ensifentrine has potential applications in cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.
FAQ
When will Verona Pharma present at the Stifel 2021 Virtual Healthcare Conference?
What is the focus of Verona Pharma's presentations in November 2021?
How can I view Verona Pharma's investor presentations?
When is the Piper Sandler 33rd Annual Virtual Healthcare Conference presentation?
